The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence

• Published in: Future Oncology Vol. 12; no. 17; pp. 2009 - 2020
• Main Authors: Gmeiner, William H, Debinski, Waldemar, Milligan, Carol, Caudell, David, Pardee, Timothy S
• Format: Journal Article Book Review
• Language: English
• Published: England Future Medicine Ltd 01.09.2016
• Subjects: acute leukemia; Animals; Antineoplastic Agents - pharmacology; Bone marrow; Brain cancer; cancer chemotherapy; Cancer therapies; Chemotherapy; Deoxyribonucleic acid; Design; DNA; DNA damage; Drug dosages; Enzymes; Fluorodeoxyuridylate - analogs & derivatives; Fluorodeoxyuridylate - pharmacology; fluoropyrimidine; glioblastoma; Humans; Leukemia; Metabolism; Metabolites; Neoplasms - drug therapy; Prostate cancer; Review; thymineless death; topoisomerase; United States > US; prostate cancer; fluoropyrimidine; glioblastoma; thymineless death; acute leukemia; cancer chemotherapy; topoisomerase
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2016-0091

F10 is a novel polymeric fluoropyrimidine drug candidate with strong anticancer activity in multiple preclinical models. F10 has strong potential for impacting cancer treatment because it displays high cytotoxicity toward proliferating malignant cells with minimal systemic toxicities thus providing an improved therapeutic window relative to traditional fluoropyrimidine drugs, such as 5-fluorouracil. F10 has a unique mechanism that involves dual targeting of thymidylate synthase and Top1. In this review, the authors provide an overview of the studies that revealed the novel aspects of F10's cytotoxic mechanism and summarize results obtained in preclinical models of acute myeloid leukemia, acute lymphocytic leukemia, glioblastoma and prostate cancer that demonstrate the strong potential of F10 to improve treatment outcomes.